دورية أكاديمية
أعرض في EDS

Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection.

التفاصيل البيبلوغرافية
العنوان: Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection.
المؤلفون: Flynn O; School of Pharmacy, University College Cork, T12 XF62 Cork, Ireland., Dillane K; School of Pharmacy, University College Cork, T12 XF62 Cork, Ireland., Lanza JS; School of Pharmacy, University College Cork, T12 XF62 Cork, Ireland., Marshall JM; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Jin J; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Silk SE; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Draper SJ; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Moore AC; School of Pharmacy, University College Cork, T12 XF62 Cork, Ireland.; School of Biochemistry and Cell Biology, University College Cork, T12 XF62 Cork, Ireland.
المصدر: Vaccines [Vaccines (Basel)] 2021 Mar 22; Vol. 9 (3). Date of Electronic Publication: 2021 Mar 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: Adenovirus-based vaccines are demonstrating promising clinical potential for multiple infectious diseases, including COVID-19. However, the immunogenicity of the vector itself decreases its effectiveness as a boosting vaccine due to the induction of strong anti-vector neutralizing immunity. Here we determined how dissolvable microneedle patches (DMN) for skin immunization can overcome this issue, using a clinically-relevant adenovirus-based Plasmodium falciparum malaria vaccine, AdHu5-PfRH5, in mice. Incorporation of vaccine into patches significantly enhanced its thermostability compared to the liquid form. Conventional high dose repeated immunization by the intramuscular (IM) route induced low antigen-specific IgG titres and high anti-vector immunity. A low priming dose of vaccine, by the IM route, but more so using DMN patches, induced the most efficacious immune responses, assessed by parasite growth inhibitory activity (GIA) assays. Administration of low dose AdHu5-PfRH5 using patches to the skin, boosted by high dose IM, induced the highest antigen-specific serum IgG response after boosting, the greatest skewing of the antibody response towards the antigen and away from the vector, and the highest efficacy. This study therefore demonstrates that repeated use of the same adenovirus vaccine can be highly immunogenic towards the transgene if a low dose is used to prime the response. It also provides a method of stabilizing adenovirus vaccine, in easy-to-administer dissolvable microneedle patches, permitting storage and distribution out of cold chain.
References: Vaccine. 2015 Jun 22;33(28):3248-55. (PMID: 25839104)
JAMA. 2016 Apr 19;315(15):1610-23. (PMID: 27092831)
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3041-6. (PMID: 23386724)
Mol Ther. 2014 Dec;22(12):2142-2154. (PMID: 25156127)
Sci Transl Med. 2010 Feb 17;2(19):19ra12. (PMID: 20371486)
Front Immunol. 2015 Jul 08;6:348. (PMID: 26217340)
J Clin Invest. 2015 Mar 2;125(3):1129-46. (PMID: 25642773)
Hum Vaccin Immunother. 2016 Nov;12(11):2975-2983. (PMID: 27050528)
J Immunol. 2017 May 1;198(9):3494-3506. (PMID: 28348274)
Eur J Immunol. 2008 Mar;38(3):732-41. (PMID: 18266272)
Sci Adv. 2020 Mar 04;6(10):eaau4819. (PMID: 32181330)
Infect Immun. 2006 Aug;74(8):4573-80. (PMID: 16861644)
Lancet Infect Dis. 2020 Jul;20(7):816-826. (PMID: 32325038)
Int J Pharm. 2016 Mar 16;500(1-2):1-10. (PMID: 26721722)
Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989)
Vaccine. 2014 Apr 1;32(16):1856-62. (PMID: 24530146)
Sci Transl Med. 2012 Jan 4;4(115):115ra1. (PMID: 22218690)
Nat Med. 2008 Aug;14(8):819-21. (PMID: 18660818)
Infect Immun. 2005 Jun;73(6):3677-85. (PMID: 15908397)
J Control Release. 2012 Apr 10;159(1):34-42. (PMID: 22245683)
PLoS One. 2011;6(10):e25868. (PMID: 22003411)
Nat Rev Microbiol. 2006 Jun;4(6):469-76. (PMID: 16710326)
Clin Infect Dis. 2008 Jun 1;46(11):1769-81. (PMID: 18433307)
Lancet. 2017 Aug 12;390(10095):649-658. (PMID: 28666680)
Vaccine. 2012 Feb 27;30(10):1847-54. (PMID: 22230592)
J Control Release. 2019 Aug 28;308:14-28. (PMID: 31265882)
Cell. 2019 Jun 27;178(1):216-228.e21. (PMID: 31204103)
Mol Ther. 2011 Dec;19(12):2269-76. (PMID: 21862998)
Nat Med. 2021 Feb;27(2):279-288. (PMID: 33335322)
Bull World Health Organ. 2008 Jan;86(1):27-39. (PMID: 18235887)
Pharm Dev Technol. 1998 Aug;3(3):373-83. (PMID: 9742558)
Hum Vaccin Immunother. 2017 Mar 4;13(3):613-620. (PMID: 28152326)
Lancet. 2020 Aug 15;396(10249):479-488. (PMID: 32702299)
Cell Host Microbe. 2015 Jan 14;17(1):130-9. (PMID: 25590760)
Biomaterials. 2015 Jul;57:50-8. (PMID: 25913250)
PLoS One. 2011;6(5):e20547. (PMID: 21655233)
Ann Intern Med. 2016 Mar 1;164(5):313-22. (PMID: 26833336)
Sci Rep. 2014 Aug 21;4:6154. (PMID: 25142082)
PLoS One. 2018 Feb 20;13(2):e0192312. (PMID: 29462200)
J Virol. 2008 Apr;82(8):3822-33. (PMID: 18256155)
Nature. 2020 Oct;586(7830):583-588. (PMID: 32731257)
Nat Immunol. 2009 Apr;10(4):375-84. (PMID: 19252493)
Sci Rep. 2018 Feb 21;8(1):3390. (PMID: 29467399)
N Engl J Med. 2016 Apr 28;374(17):1635-46. (PMID: 25629663)
NPJ Vaccines. 2019 Dec 20;4:54. (PMID: 31885877)
Nat Biotechnol. 2013 Dec;31(12):1082-5. (PMID: 24316643)
NPJ Vaccines. 2018 Aug 17;3:32. (PMID: 30131879)
Lancet. 2021 Dec 19;396(10267):1979-1993. (PMID: 33220855)
Cell Host Microbe. 2018 Jul 11;24(1):43-56. (PMID: 30001524)
PLoS One. 2011;6(7):e22442. (PMID: 21799855)
JCI Insight. 2017 Nov 2;2(21):. (PMID: 29093263)
Int J Pharm. 2020 Aug 30;586:119390. (PMID: 32540349)
J Control Release. 2016 Mar 10;225:192-204. (PMID: 26774221)
Nat Commun. 2011 Dec 20;2:601. (PMID: 22186897)
Lancet. 2017 Feb 11;389(10069):621-628. (PMID: 28017399)
Am J Respir Crit Care Med. 2017 May 1;195(9):1171-1180. (PMID: 28060545)
J Control Release. 2019 Oct;311-312:96-103. (PMID: 31484041)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust
فهرسة مساهمة: Keywords: adenovirus; anti-vector immunity; antibody; dose; microneedle; skin; stability; virus vector vaccine
تواريخ الأحداث: Date Created: 20210403 Latest Revision: 20210413
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8005075
DOI: 10.3390/vaccines9030299
PMID: 33810085
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines9030299